Bo Tan, Tao Chen, Peng Song, Feng Lin, Shuangyin He, Shiyuan Zhang, Xiaohong Yin
{"title":"综合分析揭示了乙基亚硝基源诱导胶质瘤形成的关键分子机制和预后模型。","authors":"Bo Tan, Tao Chen, Peng Song, Feng Lin, Shuangyin He, Shiyuan Zhang, Xiaohong Yin","doi":"10.1186/s40360-025-00919-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ethylnitrosourea (ENU) is a potent mutagen that induces gliomas in experimental models. Understanding the molecular mechanisms underlying ENU-induced gliomagenesis can provide insights into glioma pathogenesis and potential therapeutic targets.</p><p><strong>Methods: </strong>We analyzed gene expression data from GSE16011 and GSE4290 datasets to identify differentially expressed genes (DEGs) associated with gliomagenesis. Comparative Toxicogenomics Database (CTD) was used to identify potential ENU targets. Protein-protein interaction (PPI) network, enrichment analysis, and Cox regression analysis were employed to elucidate key genes and pathways. A risk model was constructed using the TCGA dataset by LASSO analysis, and nomogram and immuno-infiltration analyses were performed.</p><p><strong>Results: </strong>We identified 71 common genes potentially in ENU-induced gliomas. Key hub genes, including TP53, MCL1, CCND1, and PTEN, were highlighted in the PPI network. Enrichment analysis revealed significant GO terms and KEGG pathways, such as \"Neuroactive ligand-receptor interaction\" and \"Glioma.\" A risk model based on 11 prognostic genes was constructed, effectively stratifying patients into low and high-risk groups, with significant differences in overall survival. The model demonstrated high predictive accuracy. The nomogram constructed from ENU-related risk scores showed good calibration and clinical utility. Immuno-infiltration analysis indicated higher immune cell infiltration in high-risk patients. Molecular docking suggested strong binding affinities of ENU with MGMT and CA12.</p><p><strong>Conclusion: </strong>Our integrative analysis identified key genes and pathways implicated in ENU-induced gliomagenesis. The ENU-related risk model and nomogram provide significant prognostic value, offering potential tools for clinical assessment and targeted therapies in glioma patients.</p>","PeriodicalId":9023,"journal":{"name":"BMC Pharmacology & Toxicology","volume":"26 1","pages":"89"},"PeriodicalIF":2.8000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013803/pdf/","citationCount":"0","resultStr":"{\"title\":\"Integrative analysis reveals key molecular mechanisms and prognostic model for Ethylnitrosourea-induced gliomagenesis.\",\"authors\":\"Bo Tan, Tao Chen, Peng Song, Feng Lin, Shuangyin He, Shiyuan Zhang, Xiaohong Yin\",\"doi\":\"10.1186/s40360-025-00919-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Ethylnitrosourea (ENU) is a potent mutagen that induces gliomas in experimental models. Understanding the molecular mechanisms underlying ENU-induced gliomagenesis can provide insights into glioma pathogenesis and potential therapeutic targets.</p><p><strong>Methods: </strong>We analyzed gene expression data from GSE16011 and GSE4290 datasets to identify differentially expressed genes (DEGs) associated with gliomagenesis. Comparative Toxicogenomics Database (CTD) was used to identify potential ENU targets. Protein-protein interaction (PPI) network, enrichment analysis, and Cox regression analysis were employed to elucidate key genes and pathways. A risk model was constructed using the TCGA dataset by LASSO analysis, and nomogram and immuno-infiltration analyses were performed.</p><p><strong>Results: </strong>We identified 71 common genes potentially in ENU-induced gliomas. Key hub genes, including TP53, MCL1, CCND1, and PTEN, were highlighted in the PPI network. Enrichment analysis revealed significant GO terms and KEGG pathways, such as \\\"Neuroactive ligand-receptor interaction\\\" and \\\"Glioma.\\\" A risk model based on 11 prognostic genes was constructed, effectively stratifying patients into low and high-risk groups, with significant differences in overall survival. The model demonstrated high predictive accuracy. The nomogram constructed from ENU-related risk scores showed good calibration and clinical utility. Immuno-infiltration analysis indicated higher immune cell infiltration in high-risk patients. Molecular docking suggested strong binding affinities of ENU with MGMT and CA12.</p><p><strong>Conclusion: </strong>Our integrative analysis identified key genes and pathways implicated in ENU-induced gliomagenesis. The ENU-related risk model and nomogram provide significant prognostic value, offering potential tools for clinical assessment and targeted therapies in glioma patients.</p>\",\"PeriodicalId\":9023,\"journal\":{\"name\":\"BMC Pharmacology & Toxicology\",\"volume\":\"26 1\",\"pages\":\"89\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-04-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12013803/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Pharmacology & Toxicology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40360-025-00919-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Pharmacology & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40360-025-00919-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Integrative analysis reveals key molecular mechanisms and prognostic model for Ethylnitrosourea-induced gliomagenesis.
Background: Ethylnitrosourea (ENU) is a potent mutagen that induces gliomas in experimental models. Understanding the molecular mechanisms underlying ENU-induced gliomagenesis can provide insights into glioma pathogenesis and potential therapeutic targets.
Methods: We analyzed gene expression data from GSE16011 and GSE4290 datasets to identify differentially expressed genes (DEGs) associated with gliomagenesis. Comparative Toxicogenomics Database (CTD) was used to identify potential ENU targets. Protein-protein interaction (PPI) network, enrichment analysis, and Cox regression analysis were employed to elucidate key genes and pathways. A risk model was constructed using the TCGA dataset by LASSO analysis, and nomogram and immuno-infiltration analyses were performed.
Results: We identified 71 common genes potentially in ENU-induced gliomas. Key hub genes, including TP53, MCL1, CCND1, and PTEN, were highlighted in the PPI network. Enrichment analysis revealed significant GO terms and KEGG pathways, such as "Neuroactive ligand-receptor interaction" and "Glioma." A risk model based on 11 prognostic genes was constructed, effectively stratifying patients into low and high-risk groups, with significant differences in overall survival. The model demonstrated high predictive accuracy. The nomogram constructed from ENU-related risk scores showed good calibration and clinical utility. Immuno-infiltration analysis indicated higher immune cell infiltration in high-risk patients. Molecular docking suggested strong binding affinities of ENU with MGMT and CA12.
Conclusion: Our integrative analysis identified key genes and pathways implicated in ENU-induced gliomagenesis. The ENU-related risk model and nomogram provide significant prognostic value, offering potential tools for clinical assessment and targeted therapies in glioma patients.
期刊介绍:
BMC Pharmacology and Toxicology is an open access, peer-reviewed journal that considers articles on all aspects of chemically defined therapeutic and toxic agents. The journal welcomes submissions from all fields of experimental and clinical pharmacology including clinical trials and toxicology.